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The Parelsnoer Institute (PSI) is a collaborative biobanking project of all eight University Medical Centers 
in the Netherlands which was launched in 2007. Basically, PSI consists of three dimensions: participating 
institutions, disease entities and a central organization. An executive board for operational management 
instigates collective strategic and tactic policies and a central team of PSI experts and advisors supports 
the researchers and the board in establishing and implementing standards and procedures. PSI offers 
researchers an infrastructure and standard procedures for the establishment, expansion and optimisa-
tion of clinical biobanks for scientific research. To ensure patient privacy clinical data is pseudomized and 
carefully stored in a central database. Human biomaterials are collected according to nationally agreed 
standards.
Currently PSI covers fifteen large disease specific cohorts (the so-called ‘Parels’ or ‘Pearls’) and new 
‘Pearls’ are being developed. The Parelsnoer Institute currently (December 2016) has stored more than 
538,000 biospecimens with annotated clinical data of more than 30,000 patients. All these materials and 
data are available for anyone with a bona fide research proposal.
Keywords: Harmonized standards; clinical biobanking; translational medical research; health innovation; 
generic information architecture; international security and privacy standards
Funding statement: PSI started in 2007 with a five year initial grant from the Dutch Government. From 
2011 onwards PSI is supported and facilitated by the Netherlands Federation of University Medical 
Centers (NFU) and its member institutions. This means that sustainability of PSI as core infrastructure 
for applied clinical research in the Netherlands is not dependent on external funds. Additional funds from 
charities, governmental sources and industrial sponsors are used to expand PSI with new disease groups 
and for the analyses of the collections in actual research projects.
(1) Bioresource Overview
Project description
In 2007, the Netherlands Federation of University Medical 
Centers (NFU) launched the Parelsnoer Institute (PSI) [1], 
with the aim of facilitating medical research and inno-
vation ultimately leading to better diagnosis, treatment 
or even prevention of complex disorders [2–17]. PSI is 
a collaborative network of all eight Dutch University 
Medical Centers (UMCs), also known as academic teach-
ing hospitals. Figure 1 describes the organization of 
the Parelsnoer Institute. Basically, PSI consists of three 
dimensions: participating institutions (the 8 UMCs), dis-
ease entities (currently 15 disease specific groups which 
are called ‘Pearls’, still expanding) and the central organi-
zation with several expert areas. An executive board for 
operational management (see Figure 1) instigates col-
lective strategic and tactic policies. In addition, a cen-
tral team of PSI experts and advisors, working in the 
participating UMCs, supports the researchers and the 
board in establishing and implementing standards and 
procedures.
Several standard operating procedures (SOPs), regula-
tions and agreements constitute a framework of ready to 
use harmonized standards throughout the subsequent 
phases of the biobanking process. Templates provide tools 
for efficient implementation of the SOPs and use of these 
templates contributes to the level of standardization. 
Application of this framework by all UMCs yields large 
uniform collections and contributes to high quality at all 
levels.
Manniën et al: The Parelsnoer InstituteArt. 3, p. 2 of 8 
Each UMC stores biomaterials in their own certified 
biobank(s) according to the PSI biobanking protocol, 
which was developed by biobank coordinators from all 
UMCs together and covers all phases of biobanking. Each 
Pearl provides a different variety of biomaterials such as 
serum, plasma, DNA, faeces, urine, cerebrospinal fluid, 
pancreatic cyst fluid, viable cells, fresh frozen tissues 
and/or FFPE tissues. Metadata (e.g., type of material) 
from biomaterials and the unique sample code are reg-
istered in the central database together with the clinical 
data [18].
For each Pearl a specific information model is 
defined for the detailed clinical dataset including per-
sonal data and clinical data pertaining the specific 
disease [19]. The data are collected both via electronic 
and manual methods and are hosted in a validated web 
based application (ProMISe) that fulfills international 
standards for data management, quality assurance, and 
privacy protection using a Trusted Third Party [20, 21].
Classification (1)
Human.
Classification (2)
Biological samples and associated clinical data.
Context
Spatial coverage
Description:
All eight University Medical Centers across the 
Netherlands: Academic Medical Center (Amsterdam), 
Erasmus Medical Center (Rotterdam), Leiden University 
Medical Center, Maastricht University Medical Center, 
Radboud University Medical Center (Nijmegen), University 
Medical Center Groningen, University Medical Center 
Utrecht, VU University Medical Center (Amsterdam).
Northern boundary: +53.4647366.
Southern boundary: +50.757197.
Eastern boundary: +7.222824.
Western boundary: +3.364563.
Temporal coverage
Eight disease-specific bioresources started their collec-
tion in 2009. Five others started later and new collections 
will start in the (near) future. The end date might differ 
between the collections, however, so far no expected end 
date has been determined for any collection.
Temporal coverage for accessibility
The bioresources are available for use in bona fide research 
projects; no end date determined.
Figure 1: Organization of the Parelsnoer Institute.
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Sample Volume/number Processing Time Aliquoting Storage
Serum 10 ml clotted blood 2000 × g at room 
temperature or 4°C 
for 10 minutes
Within 2–4 hours ≥ 5 × 0.5 ml –80°C
EDTA plasma 10 ml 2000 × g at room 
temperature or 4°C 
for 10 minutes
Within 2–4 hours ≥ 5 × 0.5 ml –80°C
Citrate plasma 9 ml 2000 × g at room tem-
perature for 10 minutes
Within 2–4 hours ≥ 5 × 0.5 ml –80°C
DNA (blood) 10 ml EDTA blood Whole blood or 
cell pellet, to UMC 
specifications
Within 4 weeks 
(4°C) or 3 months 
(< –20°C)
≥ 2 stock 
aliquots
4°C or lower
Faeces Not specified Direct storage or after 
homogenization
Within 12 hours ≥ 5 × 5 gr –80°C
Urine +/– antioxi-
dants (AO)
Not specified, 
midstream
2000 × g at room tem-
perature or 4°C (AO) for 
10 minutes
Within 4 hours 6 aliquots 
0.9 ml
–80°C
Cerebrospinal fluid 3–20 ml 2000 × g at room 
temperature or 4°C 
for 10 minutes
Within 2 hours ≥ 6 × 0.5 ml –80°C in polypro-
pylene tubes
Biopsy FFPE n* per location# Formalin fixation and 
paraffin embedding
Immediate fixation Per set Room 
temperature
Biopsy frozen n* per location# Snap frozen in 
isopentane
Immediate Per set –80°C
Resection speci-
men FFPE
n* per location# Snap frozen in 
isopentane
At pathology 0.5 cm3 
samples
Room 
temperature
Resection 
specimen frozen
n* per location# Snap frozen in 
isopentane
At pathology 0.5 cm3 
samples
–80°C
Pancreatic cyst 
fluid
≥ 0.5 ml None Within 2–4 hours 0.5 ml 
portions
–80°C
Viable cells (PBMCs 
or bone marrow)
20–40 ml  
heparinized sample
Density centrifugation at 
room temperature
Within 24 hours 10 × 10E6 
cells per 
cryovial
–130°C
Table 1: Summary of procedures on collection, processing and storage of samples defined in the biobanking protocol 
of PSI.†
†  Deviations to be registered: hemolytic, lipemic, icteric, wrong tube, volume incorrect, storage temperature deviation, 
longer storage time, mixing/homogenization incorrect, centrifugation process different, storage problem, other 
deviation as free text.
* as specified by Pearl.
# for instance normal or affected or inflamed or tumor in intestinal tract or skin.
   PBMCs: peripheral blood mononuclear cells.
(2) Methods
Steps
For each Pearl a specific information model is defined, 
called PRISMA: Parelsnoer Repository for Information 
Specification, Modelling and Architecture. PSI adheres 
to the principle of reusing electronic health record (EHR) 
information for scientific purposes (“registration at the 
source”, http://www.nfu.nl/programma/registratie-aan-
de-bron/programma). Therefore, PRISMA is developed 
with reuse of information and with minimization of reg-
istration burden as prime directives, while also taking 
routine care procedures into account. The architecture 
is in compliance with (inter-)national classifications such 
as International Classification of Diseases and Related 
Health Problems (ICD-10), SNOMED CT and the Logical 
Observation Identifiers Names and Codes (LOINC®).
Each Pearl defines its own set of biosamples to be 
collected and stored in the biobank. Biomaterials are 
preferably collected during routine clinical proce-
dures. Samples are stored in certified UMC biobanking 
facilities which collectively constitute the federative 
PSI biobank. The biobanking protocol of PSI is imple-
mented in all the participating institutions and covers 
all phases of biobanking; from collection to storage of 
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the samples. Metadata (e.g., type of material) from bio-
materials and the unique sample code are registered 
in the central database together with the clinical data. 
The detailed clinical dataset includes personal data 
(e.g., age, gender, education level, ethnic origin, weight, 
height) and clinical data pertaining the specific disease 
(e.g., diagnosis, lab results, complications, physical 
examination, (medical) treatment, questionnaires). The 
data are collected both via electronic and manual meth-
ods and are hosted in a validated web based application 
(ProMISe) [20].
PSI also provides an infrastructure and procedures 
to uniformly collect and store images, for instance MRI 
images. Standardized source images are safely stored in 
the local Picture Archive and Communication System 
(PACS) in the UMCs. After anonymization, the images are 
subsequently uploaded in the TraIT Bio-Medical Imaging 
Archive (BMIA), which is a safe and sustainable online 
archive [22].
Stabilization/preservation
Table 1 gives a summary of procedures on collection, pro-
cessing and storage of samples defined in the biobanking 
protocol of PSI.
Type of long-term preservation 
See Table 1.
Storage temperature 
See Table 1.
Shipping temperature from patient/source to 
preservation or research use
See Table 1.
Shipping temperature from storage to research 
use
–80°C (on dry ice).
Quality assurance measures
Quality of data and quality of stored biomaterials are by 
no means self-evident. In PSI, the two most important crit-
ical success factors for adequate data quality are: to limit 
the number of elements in the information model to what 
is necessary for future research and to fully integrate the 
collection of data in the routine of the EHR. Other essen-
tial elements for adequate quality are: use international 
standards (Detailed Clinical Models), develop simple and 
logical instructions for data collection and registration, 
mandate and authorize dedicated research employees, 
and perform regular quality checks.
For biomaterials there is no possibility to improve qual-
ity afterwards. Only a strict adherence to the biobank 
protocol and related SOPs can assure quality of material 
available for research. This is under the assumption that 
SOPs describe (either evidence or consensus based) what 
is optimal for integrity of the biomaterials. In PSI, biobank 
coordinators from all UMCs together have developed the 
PSI biobanking protocol and revise them every two years. 
This involvement of all biobank coordinators in establish-
ing the protocol enhances adherence to the described pro-
cedures. The PSI biobanking protocol covers all phases of 
biobanking: collection, pre-analysis, registration, process-
ing and storage of the samples (Table 1).
Source of associated data 
The associated data are mainly coming from electronic 
health records, laboratory reports, and questionnaires. 
Each UMC has its own research IT infrastructure that 
Figure 2: IT Infrastructure of PSI.
Manniën et al: The Parelsnoer Institute Art. 3, p. 5 of 8 
delivers the data to their local database in ProMISe, 
which is a web based application. In some UMCs data 
are entered manually into the local database (mostly 
by research nurses and/or clinicians) while other 
UMCs benefit from automatic data capture directly 
from the EHR resources. The information supplied 
by each UMC is periodically uploaded, after valida-
tion, to the central database in ProMISe (one data-
base per Pearl, which is the combination of the 8 
local UMC Pearl databases) for storage on a national 
level (Figure 2). During upload of data to the local 
and central databases, identifying data are encrypted 
by special software of a Trusted Third Party (Trusted 
Reversible Encryption Service®, Houten, Utrecht, The 
Netherlands). As to further protect the privacy of the 
patients, the identifying data are encrypted again 
when exported from the central database for deliv-
ery to the researchers. In specific situations, e.g., in 
case of incidental findings that need feedback to the 
patient or necessary data-linkage, depseudonymiza-
tion is possible by authorized personnel only. The PSI 
IT infrastructure is compliant with international secu-
rity and privacy standards.
(3) Bioresource description
Object name
The Parelsnoer Institute.
Bioresource name 
The Parelsnoer Institute (PSI).
Bioresource location 
All eight University Medical Centers across the Netherlands 
participate in PSI:
1. Academic Medical Center, Meibergdreef 9, 1105 AZ 
Amsterdam, The Netherlands
2. Erasmus Medical Center, ’s-Gravendijkwal 230, 3015 
CE Rotterdam, The Netherlands
3. Leiden University Medical Center, Albinusdreef 2, 
2333 ZA Leiden, The Netherlands
4. Maastricht University Medical Center, P. Debyelaan 
25, 6229 HX Maastricht, The Netherlands
5. Radboud University Medical Center, Geert 
Grooteplein-Zuid 10, 6525 GA Nijmegen, The 
Netherlands
6. University Medical Center Groningen, Hanzeplein 1, 
9713 GZ Groningen, The Netherlands
7. University Medical Center Utrecht, Heidelberglaan 
100, 3584 CX Utrecht, The Netherlands
8. VU University Medical Center, De Boelelaan 1117, 
1081 HV Amsterdam, The Netherlands
Bioresource contact 
Parelsnoer Institute, Jaarbeursplein 6, 3521 Al Utrecht, 
The Netherlands.
Email: info@parelsnoer.org
Bioresource URL
http://parelsnoer.org/page/en/Home.
Identifier used 
N/A.
Bioresource type 
PSI is a collaborative clinical biobank, comprising a num-
ber of disease specific national bioresources (the Pearls). 
All types of pathology and disease samples are stored (see 
Table 1). To date (October 2016) the following fifteen dis-
ease categories are included:
– Abdominal aortic aneurysm
– Congenital heart disease
– Cerebrovascular accident
– Diabetes 
– Hereditary colorectal cancer
– Inflammatory bowel disease
– Ischemic heart disease
– Leukemia, myeloma and lymphoma
– Multiple endocrine neoplasia
– Neurodegenerative diseases
– Oesophageal and gastric cancer
– Pancreatic cancer and pancreatitis
– Renal failure
– Rheumatoid arthritis and arthrosis
– Parkinson’s disease
Type of sampling
PSI consists of disease based cohorts with longitudinal col-
lections, sampled in clinical care.
Anatomical site 
The fifteen Pearls cover several anatomical sites of the 
human body.
Disease status of patients/source
See the fifteen Pearls/diseases mentioned above.
Clinical characteristics of patients/source
A full clinical characterization, including extensive diag-
nostics, demographics, therapeutics and clinical follow-up 
is specified for each disease specific bioresource.
Vital state of patients/source
All patients are alive at inclusion.
Clinical diagnosis of patients/source
PSI covers several significant diseases, presently fifteen: 
Abdominal aortic aneurysm, Congenital heart disease, 
Cerebrovascular accident, Diabetes, Hereditary colorectal 
cancer, Inflammatory bowel disease, Ischemic heart dis-
ease, Leukemia, myeloma and lymphoma, Multiple endo-
crine neoplasia, Neurodegenerative diseases, Oesophageal 
and gastric cancer, Pancreatic cancer and pancreati-
tis, Renal failure, Rheumatoid arthritis and arthrosis, 
Parkinson’s disease.
Pathology diagnosis
The architecture is in compliance with (inter-)national 
classifications such as International Classification of 
Diseases and Related Health Problems (ICD-10), SNOMED 
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CT and the Logical Observation Identifiers Names and 
Codes (LOINC®).
Control samples
The Parelsnoer Institute does not collect control sam-
ples from healthy individuals. If needed controls can be 
obtained from LifeLines, a national longitudinal popula-
tion biobank in the Netherlands [24].
Biospecimen type 
Each Pearl provides a different variety of biomaterials such 
as serum, plasma, DNA, RNA, faeces, urine, cerebrospinal 
fluid, pancreatic cyst fluid, viable cells, fresh frozen tissues 
and/or FFPE tissues. Table 1 gives a summary of proce-
dures on collection, processing and storage of samples 
defined in the biobanking protocol of PSI.
Size of the bioresource 
In total, clinical data of more than 32,000 patients and 
538,000 biospecimens of more than 30,000 patients are 
available. PSI has no end date. The current number of 
included patients per Pearl is shown in Table 2.
Release date
Data and samples are currently available. PSI releases data 
and samples to research projects on a regular basis. Thus 
far, the research projects have led to many scientific pub-
lications [3–17].
Access criteria
A catalogue, i.e., an open access searchable database on the 
internet, provides up-to-date information about the con-
tent of all PSI collections [18]. This gives researchers the 
opportunity to discover for what type of patients which 
type and amount of data and biomaterials are available. 
Every researcher worldwide may submit a study proposal 
to the Pearl and request data, biomaterials and/or images.
A scientific committee of the Pearl (consisting of repre-
sentatives of the Pearl and independent scientific experts) 
judges whether the proposed study is relevant, compli-
ant with the scientific aims of the Pearl, methodologically 
sound, compliant with privacy protection rules and feasi-
ble in relation to the amount of biomaterial requested. In 
addition, permission from the Research Ethical Committee 
of the coordinating UMC has to be obtained and from 
some other participating centers according to local policy. 
When permissions have been granted and request forms 
are completed, the PSI data manager will deliver the data 
(and images if needed) from the central PSI facilities to 
the researcher. The biobank coordinators of the UMCs will 
deliver the requested biomaterials. If scientific analyses in 
research projects yield new data, PSI demands these newly 
acquired (individual) data to be made available for future 
research purposes. 
Costs vary depending on the type and amount of sam-
ples. An economic quotation is sent covering shipping 
costs and partially costs for biobanking-related services 
(sample handling, consumables).
 (4) Reuse potential
Samples from the same donor may be used in several dif-
ferent projects. As a condition of supply of material, the 
recipient of samples and/or data must agree to return 
findings to PSI on conclusion of the research purpose. 
These newly acquired (individual) data are then available 
for future research purposes. Besides, the applicant must 
Pearl† Number of patients with 
clinical data
Number of patients with 
biomaterials
Congenital heart disease 5400 5400
Cerebrovascular accident 5815 5374
Diabetes 6673 6226
Hereditary colorectal cancer 1853 1534
Inflammatory bowel disease 4642 4139
Ischemic heart disease 632 412
Leukemia, myeloma and lymphoma 1755 1596
Neurodegenerative disease 1213 1122
Esophageal and gastric cancer 122 93
Pancreatic cancer and pancreatitis 318 282
Renal failure 1991 1963
Rheumatoid arthritis and arthrosis 2277 2190
Table 2: The number of included patients per Pearl.*
* dd December 12, 2016.
† Three Pearls (i.e., Multiple Endocrine Neoplasia, Abdominal Aortic Aneurysm and Parkinson’s Disease) started recently 
and to date (December 2016) have not yet included patients.
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acknowledge PSI in all publications resulting from the use 
of these data and samples and provide a copy of the pub-
lished paper to PSI.
Ethics Statement
PSI provides a regulatory framework in which ethical 
guidelines, in accordance with (inter-)national legislation 
and rules, are described [23]. Supported by a member 
of the PSI Central Team, each Pearl composes a patient 
information brochure, a consent form and regulations. 
These documents together with the strategic plan of the 
Pearl are reviewed by the Medical Ethical Committee of 
the coordinating UMC. Subsequently, Medical Ethical 
Committees and Board of Directors of the remaining par-
ticipating UMCs have to approve local implementation of 
the Pearl’s biobanking activities. Patients included in the 
Pearl give written informed consent prior to inclusion.
Constraints
Only patients who provided written informed consent are 
included, no healthy controls. Participants may withdraw 
their consent at all times. The patient can express the wish 
to withdraw to his/her doctor, in which case the doctor 
will ensure that data and materials are destroyed unless 
needed for validation of earlier issuance.
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